Molecular Templates Share Holder Equity 2010-2024 | MTEM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Molecular Templates share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Molecular Templates share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$77.1B
Chugai Pharmaceutical (CHGCY)	$71.1B
Takeda Pharmaceutical (TAK)	$42.6B
Sandoz Group AG (SDZNY)	$21B
Merck (MKKGY)	$19.6B
Astellas Pharma (ALPMY)	$17.5B
Summit Therapeutics (SMMT)	$15.9B
United Therapeutics (UTHR)	$15.7B
Neurocrine Biosciences (NBIX)	$15.4B
Shionogi (SGIOY)	$13B
Orion OYJ (ORINY)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.3B
Corcept Therapeutics (CORT)	$7B
Stevanato Group S.p.A (STVN)	$6.8B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ionis Pharmaceuticals (IONS)	$5B
Grifols, S.A (GRFS)	$4.7B
Ono Pharmaceutical (OPHLF)	$4.3B
Crinetics Pharmaceuticals (CRNX)	$3.7B
Recursion Pharmaceuticals (RXRX)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Centessa Pharmaceuticals (CNTA)	$2.2B
Soleno Therapeutics (SLNO)	$2.2B
NewAmsterdam Pharma (NAMS)	$2.1B
Hypermarcas (HYPMY)	$2B
Indivior (INDV)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Evotec AG (EVO)	$1.6B
Dyne Therapeutics (DYN)	$1.4B